LU93049I2 - Susoctocog - Google Patents

Susoctocog Download PDF

Info

Publication number
LU93049I2
LU93049I2 LU93049C LU93049C LU93049I2 LU 93049 I2 LU93049 I2 LU 93049I2 LU 93049 C LU93049 C LU 93049C LU 93049 C LU93049 C LU 93049C LU 93049 I2 LU93049 I2 LU 93049I2
Authority
LU
Luxembourg
Prior art keywords
factor viii
inhibitory antibodies
amino acid
modified factor
loci
Prior art date
Application number
LU93049C
Other languages
English (en)
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of LU93049I2 publication Critical patent/LU93049I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
LU93049C 2000-03-10 2016-04-27 Susoctocog LU93049I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (fr) 2000-03-10 2001-02-16 Facteur viii modifie

Publications (1)

Publication Number Publication Date
LU93049I2 true LU93049I2 (fr) 2016-06-27

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93049C LU93049I2 (fr) 2000-03-10 2016-04-27 Susoctocog

Country Status (35)

Country Link
US (3) US6458563B1 (fr)
EP (1) EP1280540B1 (fr)
JP (1) JP4044337B2 (fr)
KR (1) KR100485525B1 (fr)
CN (1) CN1191360C (fr)
AT (1) ATE391512T1 (fr)
AU (2) AU3841601A (fr)
BE (1) BE2016C024I2 (fr)
BR (2) BR122013026957A8 (fr)
CA (1) CA2400295C (fr)
CY (2) CY1108179T1 (fr)
CZ (1) CZ298250B6 (fr)
DE (1) DE60133541T2 (fr)
DK (1) DK1280540T3 (fr)
EE (1) EE05075B1 (fr)
ES (1) ES2304379T3 (fr)
FR (1) FR16C0016I2 (fr)
HU (2) HU227804B1 (fr)
IL (2) IL151371A0 (fr)
LT (1) LTC1280540I2 (fr)
LU (1) LU93049I2 (fr)
ME (1) MEP8209A (fr)
MX (1) MXPA02008798A (fr)
NL (1) NL300808I2 (fr)
NO (2) NO331935B1 (fr)
NZ (1) NZ520799A (fr)
PL (1) PL202936B1 (fr)
PT (1) PT1280540E (fr)
RS (1) RS50364B (fr)
RU (1) RU2285724C2 (fr)
SI (1) SI1280540T1 (fr)
SK (1) SK286205B6 (fr)
UA (1) UA75064C2 (fr)
WO (1) WO2001068109A1 (fr)
ZA (1) ZA200206810B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
EP1351986A2 (fr) * 2001-01-12 2003-10-15 The American National Red Cross Methodes et compositions permettant de reduire la clairance du facteur viii, mediee par l'heparan-sulfate proteoglycane
ATE417618T1 (de) * 2001-10-05 2009-01-15 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2526120A1 (fr) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
PL1636261T3 (pl) * 2003-06-26 2007-12-31 Merck Patent Gmbh Białka trombopoetynowe o ulepszonych właściwościach
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
SI1750733T1 (sl) * 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
WO2005123928A1 (fr) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production du facteur viii de coagulation humain à partir de cellules végétales et de plantes entières
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
WO2006063031A2 (fr) 2004-12-06 2006-06-15 Haplomics Variants alleliques du facteur viii humain
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007065691A2 (fr) 2005-12-07 2007-06-14 Technische Universität München Petits ligands d'affinite peptidiques et peptido-mimetiques pour le facteur viii et pour des proteines similaires au facteur viii
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2673459C (fr) * 2006-12-22 2016-09-13 Stefan Schulte Facteurs de coagulation modifies presentant une demi-vie in vivo prolongee
EP1935430A1 (fr) * 2006-12-22 2008-06-25 CSL Behring GmbH Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (fr) 2007-05-04 2008-11-05 Novo Nordisk A/S Amélioration des titres de polypeptide de facteur VIII dans les cultures cellulaires
JP2011502478A (ja) 2007-11-01 2011-01-27 ユニバーシティー オブ ロチェスター 安定性が増大した組換え型第ｖｉｉｉ因子
EP2149603A1 (fr) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
CA2780763A1 (fr) * 2009-11-13 2011-05-19 Puget Sound Blood Center Variants d'epitopes des lymphocytes t du facteur viii a immunogenicite reduite
WO2011069164A2 (fr) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Polypeptides chimériques et hybrides de facteur viii-fc, et procédés d'utilisation de ceux-ci
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
EP3508573A1 (fr) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systèmes de traitement de facteur viii et procédés associés
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
EP2661488A1 (fr) * 2011-01-05 2013-11-13 Expression Therapeutics, LLC Procédé et système pour la culture cellulaire en suspension
CA2838833A1 (fr) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Composes pro-coagulants et leurs procedes d'utilisation
AU2012282875B2 (en) 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
WO2013016454A1 (fr) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Dosages pour la surveillance de troubles hémostatiques
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
SMT201800586T1 (it) 2012-01-12 2019-01-11 Bioverativ Therapeutics Inc Riduzione dell'immunogenicita' contro il fattore viii negli individui che si sottopongono alla terapia con fattore viii
EP2804623B1 (fr) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Facteur viii chimérique et polypeptides et leurs utilisations
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
EP2666782A1 (fr) * 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
EP2863940A4 (fr) 2012-06-08 2016-08-10 Biogen Ma Inc Facteurs de coagulation chimériques
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP3404105A1 (fr) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (fr) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Procédé d'utilisation de polypeptide du facteur viii
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
MX2015016567A (es) 2013-06-28 2016-03-31 Biogen Ma Inc Enlazador escindible por trombina con xten y usos del mismo.
WO2015021423A2 (fr) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification de molécules chimères du facteur viii
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EA201690817A1 (ru) 2013-10-22 2016-08-31 Дбв Текнолоджиз Способ лечения гемофилии индукцией толерантности к факторам крови
WO2015070014A1 (fr) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Composé de fusion procoagulant
EP3082848B1 (fr) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Outils pharmacocinétiques de population et leurs utilisations
EP2881463A1 (fr) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variants du facteur IX présentant une activité de coagulation en l'absence de leur cofacteur et/ou à une activité de coagulation F.IX accrue et leur utilisation pour traiter des troubles de saignement
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
EP3102589A1 (fr) 2014-02-04 2016-12-14 Biogen MA Inc. Chromatographie par échange cationique utilisée dans le mode de fixation par écoulement pour enrichir les modifications post-traductionnelles
US20170051041A1 (en) * 2014-02-19 2017-02-23 Kathleen Pratt Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (fr) 2014-03-05 2021-11-17 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
WO2016004113A1 (fr) 2014-06-30 2016-01-07 Biogen Ma Inc. Gène du facteur ix optimisé
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
TWI823830B (zh) 2015-11-13 2023-12-01 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
CN116479001A (zh) 2015-11-13 2023-07-25 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
EP3622065A1 (fr) 2017-05-09 2020-03-18 Emory University Variants du facteur de coagulation et leur utilisation
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
WO2019195055A1 (fr) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Particules implantables et procédés associés
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
KR20210034013A (ko) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
BR112021025426A2 (pt) 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
EP3986481A2 (fr) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Méthode de traitement avec une thérapie génique à base de virus
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN114981299A (zh) 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
JP2024514307A (ja) * 2021-03-31 2024-04-01 ヘモネティクス・コーポレーション 血液凝固測定装置の品質管理配合物
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
IL310997A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Factor VIII gene optimization
EP4408874A1 (fr) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Acides nucléiques codant pour des polypeptides du facteur viii à immunogénicité réduite
CN120035657A (zh) 2022-10-11 2025-05-23 西吉隆医疗股份有限公司 用于治疗疾病的经工程化的细胞和可植入元件
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (fr) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production de facteur VIII et produits apparentés
AU5772886A (en) * 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
ATE140027T1 (de) * 1989-12-01 1996-07-15 Pharming Bv Herstellung rekombinanter polypeptide durch rinder und transgene methoden
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003191A1 (fr) 1995-07-11 1997-01-30 Chiron Corporation Nouveaux analogues de polypeptides du facteur viii:c comprenant des domaines ou des sous-domaines du facteur v
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
EP1319016A4 (fr) * 2000-09-19 2006-05-10 Univ Emory Facteur viii modifie
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
NL300808I1 (fr) 2016-05-18
EE200200510A (et) 2004-02-16
CA2400295C (fr) 2012-01-10
NO2016007I1 (no) 2016-05-10
KR100485525B1 (ko) 2005-04-28
BRPI0109131B1 (pt) 2020-08-25
EP1280540A4 (fr) 2004-11-03
CY1108179T1 (el) 2014-02-12
BE2016C024I2 (fr) 2020-01-30
FR16C0016I2 (fr) 2018-11-02
CZ298250B6 (cs) 2007-08-01
CY2016011I1 (el) 2016-10-05
US7012132B2 (en) 2006-03-14
EE05075B1 (et) 2008-10-15
HU227804B1 (en) 2012-03-28
EP1280540A1 (fr) 2003-02-05
RS50364B (sr) 2009-11-10
BR122013026957A2 (fr) 2004-12-07
US6458563B1 (en) 2002-10-01
PL359672A1 (en) 2004-09-06
EP1280540B1 (fr) 2008-04-09
MXPA02008798A (es) 2003-04-25
CA2400295A1 (fr) 2001-09-20
ATE391512T1 (de) 2008-04-15
YU68002A (sh) 2005-11-28
UA75064C2 (en) 2006-03-15
JP4044337B2 (ja) 2008-02-06
LTC1280540I2 (lt) 2020-05-25
JP2003526358A (ja) 2003-09-09
SK286205B6 (sk) 2008-05-06
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
NZ520799A (en) 2004-06-25
RU2002124123A (ru) 2004-03-27
PT1280540E (pt) 2008-06-09
SI1280540T1 (sl) 2008-08-31
CZ20023346A3 (cs) 2003-01-15
DK1280540T3 (da) 2008-07-14
HUP0300586A2 (hu) 2003-06-28
AU3841601A (en) 2001-09-24
NO20024296L (no) 2002-11-08
US7122634B2 (en) 2006-10-17
CN1191360C (zh) 2005-03-02
HUP0300586A3 (en) 2006-11-28
HK1051004A1 (en) 2003-07-18
NL300808I2 (nl) 2020-12-21
CN1416348A (zh) 2003-05-07
ME00601B (fr) 2011-12-20
AU2001238416B2 (en) 2004-09-02
US20030068785A1 (en) 2003-04-10
PL202936B1 (pl) 2009-08-31
IL151371A (en) 2010-12-30
HUS1600020I1 (hu) 2016-06-28
CY2016011I2 (el) 2016-10-05
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
BRPI0109131B8 (pt) 2021-07-06
DE60133541D1 (de) 2008-05-21
BR122013026957A8 (pt) 2017-02-21
MEP8209A (en) 2011-12-20
NO2016007I2 (no) 2016-05-10
ES2304379T3 (es) 2008-10-16
KR20020081426A (ko) 2002-10-26
FR16C0016I1 (fr) 2016-04-29
DE60133541T2 (de) 2009-05-07
NO331935B1 (no) 2012-05-07
WO2001068109A1 (fr) 2001-09-20
IL151371A0 (en) 2003-04-10
SK14392002A3 (sk) 2003-06-03
BR0109131A (pt) 2004-12-07

Similar Documents

Publication Publication Date Title
NO2016007I2 (no) Susoktokog
PT1200105E (pt) Factor viii modificado
DK1200418T3 (da) Nematodicide trifluorbutener
DE50012238D1 (de) Desinfizierendes waschen empfindlicher textilien mit persäuren
ATE254461T1 (de) Behandlung von augenschmerzen
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
TR200200278T2 (tr) Kalsilitik bileşimler
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
ATE390144T1 (de) Behandlung von fibrosen
UA41558A (uk) Лікарський засіб для лікування ран "поліфен"
ATE297745T1 (de) Chemische modifizierung von harn von säugern